Summary statistics - qualitative results

EQA round: IGIT1/25 - Immunopathology of GIT

Deadline: 7.3.2025

Setup: groups - M (measurement principle)

AV = assigned value
CVP = consensus of all participants
>>> ... expected result
> ... acceptable result
± ... result not assessed

N_{tot} = total number of the results
N_{rel} = relative number of the results

N_{eva} = number of the results assessed
N_{suc} = number of successful results
S_{rel} = relative success

Test / Sample / Group	AV		Frequency of the results N_{tot}	N_{rel} [%]	Result	Success N_{eva}	N_{suc}	S_{rel} [%]
Set 1								
(595) **anti-gliadin IgA (deamidated)**			78			78	78	100
Sample A1			78			78	78	100
(1) Fluorescent methods	CVP	>>>	1	1,3	Positive			
(2) EIA methods	CVP	>>>	52	67	Positive			
(5) LIA, ILMA	CVP	>>>	22	28	Positive			
(99) Another measurement principle	CVP	>>>	3	3,8	Positive			
Sample B1			78			78	78	100
(1) Fluorescent methods	CVP	>>>	1	1,3	Negative			
(2) EIA methods	CVP	>>>	52	67	Negative			
(5) LIA, ILMA	CVP	>>>	22	28	Negative			
(99) Another measurement principle	CVP	>>>	3	3,8	Negative			
(594) **anti-gliadin IgG (deamidated)**			81			81	80	99
Sample A1			81			81	80	99
(1) Fluorescent methods	CVP	>>>	1	1,2	Positive			
(2) EIA methods			1	1,2	Negative			
	CVP	>>>	53	65	Positive			
(5) LIA, ILMA	CVP	>>>	23	28	Positive			
(99) Another measurement principle	CVP	>>>	3	3,7	Positive			
Sample B1			81			81	81	100
(1) Fluorescent methods	CVP	>>>	1	1,2	Negative			
(2) EIA methods	CVP	>>>	54	67	Negative			
(5) LIA, ILMA	CVP	>>>	23	28	Negative			
(99) Another measurement principle	CVP	>>>	3	3,7	Negative			
Set 2								
(424) **anti-endomysium IgA**			72			72	71	99
Sample A2			72			72	71	99
(1) Fluorescent methods			1	1,4	Inconclusive result (borderline)			
	CVP	>>>	70	97	Positive			
(2) EIA methods	CVP	>>>	1	1,4	Positive			
Sample B2			72			72	72	100
(1) Fluorescent methods	CVP	>>>	71	99	Negative			
(2) EIA methods	CVP	>>>	1	1,4	Negative			
(425) **anti-transglutaminase IgA**			86			86	86	100
Sample A2			86			86	86	100
(1) Fluorescent methods	CVP	>>>	2	2,3	Positive			
(2) EIA methods	CVP	>>>	57	66	Positive			
(5) LIA, ILMA	CVP	>>>	25	29	Positive			
(99) Another measurement principle	CVP	>>>	2	2,3	Positive			
Sample B2			86			86	86	100
(1) Fluorescent methods	CVP	>>>	2	2,3	Negative			
(2) EIA methods	CVP	>>>	57	66	Negative			
(5) LIA, ILMA	CVP	>>>	25	29	Negative			
(99) Another measurement principle	CVP	>>>	2	2,3	Negative			
Set 3								
(592) **anti-Saccharomyces cerevisiae IgA**			67			67	66	99
Sample A3			67			67	67	100
(1) Fluorescent methods	CVP	>>>	25	37	Positive			
(2) EIA methods	CVP	>>>	40	60	Positive			
(5) LIA, ILMA	CVP	>>>	2	3	Positive			
Sample B3			67			67	66	99
(1) Fluorescent methods	CVP	>>>	25	37	Negative			
(2) EIA methods	CVP	>>>	39	58	Negative			
			1	1,5	Positive			
(5) LIA, ILMA	CVP	>>>	2	3	Negative			
(593) **anti-Saccharomyces cerevisiae IgG**			59			59	58	98
Sample A3			59			59	59	100
(1) Fluorescent methods	CVP	>>>	19	32	Positive			
(2) EIA methods	CVP	>>>	38	64	Positive			
(5) LIA, ILMA	CVP	>>>	2	3,4	Positive			
Sample B3			59			59	58	98
(1) Fluorescent methods	CVP	>>>	19	32	Negative			
(2) EIA methods	CVP	>>>	37	63	Negative			

Summary statistics - qualitative results

EQA round: IGIT1/25 - Immunopathology of GIT

Deadline: 7.3.2025

Setup: groups - M (measurement principle)

Test / Sample / Group	AV	N_{tot}	N_{rel} [%]	Result	N_{eva}	N_{suc}	S_{rel} [%]
		1	1,7	Positive			
(5) LIA, ILMA	CVP >>>	2	3,4	Negative			